Accuray Inc., the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions, today announced that the U.S. Food and Drug Administration has granted the company 510(k) clearance for the marketing of the Dose Control System (DCS) for their TomoTherapy System in the United States. Accuray stated that the DCS feature allows for even higher precision in the dose stability throughout rotational treatments of image-guided radiation therapy in the TomoTherapy System by automatically adjusting controls to limit interruptions and ensuring steadiness over longer duration treatments. Customers can expect higher satisfaction, better patient experience and improved overall performance when the DCS feature is used.
“FDA clearance of the new Dose Control System is a positive step toward improving TomoTherapy System performance and customer satisfaction,” said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray in a press release on Tuesday. “We are dedicated to offering our customers technological advancements that help streamline their workflow and expand the capabilities of their systems.”
When the TomoTherapy system was introduced it revolutionized radiation therapy by providing the option to deliver slices of radiation precisely to target areas without harming surrounding healthy tissue. The advent of this new DCS feature will break new ground by providing an even higher precision of dose stability throughout complex rotational treatments. DCS feature automates what used to be a manual process thus allowing small variations to be immediately corrected which will be especially good for the long treatment procedures like Total Marrow and Total Body Irradiation.
Accuray creates technologies that are used in 582 systems installed in hospitals worldwide that have treated over 200,000 patients. Their key technologies deliver radio surgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy and adaptive radiation therapy.
For more information on the Dose Control System or Accuray, please visit www.accuray.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
